Rxo (RXO) Non-Current Deferred Tax Liability (2021 - 2025)
Historic Non-Current Deferred Tax Liability for Rxo (RXO) over the last 5 years, with Q4 2025 value amounting to $136.0 million.
- Rxo's Non-Current Deferred Tax Liability fell 1111.11% to $136.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $136.0 million, marking a year-over-year decrease of 1111.11%. This contributed to the annual value of $136.0 million for FY2025, which is 1111.11% down from last year.
- As of Q4 2025, Rxo's Non-Current Deferred Tax Liability stood at $136.0 million, which was down 1111.11% from $54.0 million recorded in Q3 2025.
- Rxo's 5-year Non-Current Deferred Tax Liability high stood at $153.0 million for Q4 2024, and its period low was $1.0 million during Q1 2024.
- Moreover, its 5-year median value for Non-Current Deferred Tax Liability was $49.0 million (2022), whereas its average is $60.6 million.
- In the last 5 years, Rxo's Non-Current Deferred Tax Liability crashed by 9375.0% in 2024 and then skyrocketed by 760000.0% in 2025.
- Quarter analysis of 5 years shows Rxo's Non-Current Deferred Tax Liability stood at $67.0 million in 2021, then tumbled by 35.82% to $43.0 million in 2022, then fell by 18.6% to $35.0 million in 2023, then soared by 337.14% to $153.0 million in 2024, then dropped by 11.11% to $136.0 million in 2025.
- Its Non-Current Deferred Tax Liability was $136.0 million in Q4 2025, compared to $54.0 million in Q3 2025 and $75.0 million in Q2 2025.